01 Adoption of Advanced Analytical Characterization Technologies The need for precise comparison between biosimilars and reference biologics is increasing the use of advanced analytical methods that assess structural, physicochemical, and functional characteristics. FDA guidance identifies comparative analytical studies as the foundation of biosimilar development, while newer approaches are designed to detect relevant product differences with greater sensitivity. This shift can strengthen evidence of biosimilarity and may reduce the need for some additional clinical testing when scientifically justified.
02 Development of Biosimilars for High-Cost Biologic Therapies The high cost of many biologic medicines is encouraging developers to pursue biosimilar versions of established therapies with significant treatment costs. FDA reported that biosimilars generated $20 billion in U.S. healthcare savings during 2024, highlighting the economic impact of competition from these products. This development can expand access to biologic treatments while creating lower-cost alternatives for therapies used in areas such as cancer and autoimmune diseases.
01 Biologic Cost Reduction and Patent Expiry Drive Market The high cost of biologic therapies creates demand for lower-cost treatment alternatives that can improve affordability for patients and healthcare systems. FDA reports that biosimilars generated about $56.2 billion in U.S. healthcare savings from 2015 through 2024, including $20.2 billion in savings during 2024 alone. For example, biosimilars used in oncology, autoimmune diseases, and diabetes can provide additional treatment options when biologic costs create access challenges. This cost-management need supports biosimilar adoption and encourages manufacturers to supply competitively priced biologic alternatives.The expiry of reference-product exclusivity creates opportunities for manufacturers to enter biologic markets with biosimilar alternatives. FDA states that a biosimilar application generally cannot be approved until 12 years after the reference product was first licensed in the U.S., subject to applicable exclusivities and other requirements. For example, FDA approved 18 biosimilars for 10 reference products during 2025, including biosimilars referencing Novolog, Xolair, and Perjeta. This market-entry opportunity supports biosimilar development and broadens the supply of biologic treatment alternatives.
01 Pricing Pressure and Limited Awareness Restrain Market Expansion Pricing pressure and low profit margins can arise as biosimilar manufacturers compete by offering lower prices than reference biologics. FDA reports that biosimilars in the U.S. typically launched with initial list prices 15% to 35% below reference products, creating strong price competition. Lower prices can reduce potential returns and make investment in additional biosimilar products less attractive, limiting manufacturer participation and slowing market expansion.Limited awareness of biosimilar equivalence can create uncertainty among physicians and patients about the safety, effectiveness, and quality of biosimilars. FDA has identified improving communication and understanding among clinicians, payers, and patients as an important part of increasing biosimilar adoption, while its 2025 fact sheet notes that provider hesitancy and patient concerns about switching persist. This uncertainty can reduce prescribing and switching decisions, slowing biosimilar adoption and market growth.
01 Biosimilar CDMO Services and Patient Support Programs Offers Growth Opportunities Biosimilar developers and pharmaceutical companies can use CDMO partners for cell-line development, process development, analytical development, and commercial manufacturing. Samsung Biologics reports 845 kL of total biomanufacturing capacity and 145+ global clients, creating revenue through development contracts, manufacturing agreements, and long-term production partnerships.Biosimilar manufacturers, specialty pharmacies, and healthcare providers can provide treatment education, reimbursement assistance, and patient support services to improve treatment continuity. Sandoz reported 1.915 million patient treatments with its biosimilars in 2025 and provides patient and provider support for products such as Tyruko, creating additional value through support programs and stronger product adoption.
01 Biological Input Supply and Market Access Complexity Hinders Growth Biosimilar manufacturers depend on specialized cell lines, culture media, filtration materials, chromatography resins, and other inputs that must meet stringent quality specifications. Unavailability of component materials and manufacturing supplies can affect the production of biological products and disrupt manufacturing continuity. Such interruptions can increase procurement costs, delay manufacturing, and make it harder for companies to maintain consistent product availability.Biosimilar developers may face additional requirements when seeking interchangeability, which can affect pharmacy-level substitution depending on state laws. Evolving requirements can complicate commercialization strategies and create additional planning and evidence-generation needs for manufacturers seeking broader market access. These complexities can delay product uptake and make market expansion more difficult.
June 2026 Samsung Bioepis expanded its biosimilar portfolio with additional commercialization activities across oncology, immunology, and ophthalmology therapies. The company continued strengthening global access to cost-effective biologic medicines through regulatory approvals and market launches.
March 2026 Celltrion expanded its biosimilar pipeline with new product launches and regulatory submissions across major therapeutic areas. The company focused on increasing availability of antibody-based biosimilars for autoimmune diseases and cancer treatments.
January 2026 Amgen expanded its biosimilars business with continued global commercialization of oncology and inflammatory disease biosimilar products. The company focused on improving patient access to affordable biologic therapies.
October 2025 Biocon Biologics expanded its biosimilar manufacturing and commercialization capabilities through new product introductions and market expansion initiatives. The company continued strengthening its position in affordable biologic treatments.